) causes renal cancer and is known to inactivate p53. G 2/mitosis (M) arrest contributes to stabilization of p53-deficient mutated cells, but its role and regulation in Cd 2ϩ -exposed p53-deficient renal cells are unknown. In p53-inactivated kidney proximal tubule (PT) cells, comet assay experiments showed that Cd 2ϩ (50 -100 M) induced DNA damage within 1-6 h. This was associated with peak formation of reactive oxygen species (ROS) at 1-3 h, measured with dihydrorhodamine 123, and G 2/M cell cycle arrest at 6 h, which were abolished by the antioxidant ␣-tocopherol (100 M). Cd 2ϩ -induced G2/M arrest was enhanced approximately twofold on release from cell synchronization (double thymidine block or nocodazole) and resulted in approximately twofold increase of apoptosis, indicating that G 2/M arrest mirrors DNA damage and toxicity. The Chk1/2 kinase inhibitor UCN-01 (0.3 M), which relieves G 2/M transition block, abolished Cd 2ϩ -induced G2 arrest and increased apoptosis. This was accompanied by prevention of Cd 2ϩ -induced cyclin-dependent kinase cdc2 phosphorylation at tyrosine 15, as shown by immunofluorescence microscopy and immunoblotting. The data indicate that in p53-inactivated PT cells Cd 2ϩ -induced ROS formation and DNA damage trigger signaling of checkpoint activating kinases ataxia telangiectasia-mutated kinase (ATM) and ataxia telangiectasia and Rad3-related kinase (ATR) to cause G 2/M arrest. This may promote survival of premalignant PT cells and Cd 2ϩ carcinogenesis.
7-hydroxystaurosporine; cyclin-dependent kinase; p21 WAF1/CIP1 ; cyclin; DNA strand breaks CELLS RESPOND TO DNA DAMAGE either by undergoing cell cycle arrest, to facilitate DNA repair, or by developing apoptotic death to eliminate excessively damaged and potentially harmful cells (1, 34, 63) . Cell cycle checkpoint control mechanisms delay cell cycle progression, thus giving altered and potentially harmful cells time to repair and/or to initiate apoptosis induction (36) . The extent of DNA damage determines whether arrest and DNA repair prevail or whether apoptosis is initiated. If DNA repair occurs, specific enzymes reverse or fix the damage (3) .
The tumor suppressor p53 regulates DNA damage-induced cell cycle arrest (53, 54) by directly stimulating the expression of p21 WAF1/CIP1 , an inhibitor of cyclin-dependent kinases (Cdks). Cdks are key regulators of the cell cycle, working together with their partners, the cyclin proteins, to ensure that, for example, DNA replication in the S phase follows from the G 1 resting phase (32) . Through its negative effects on various Cdks, p21 WAF1/CIP1 inhibits both the G 1 /S and the G 2 /mitosis (M) transitions. For instance, according to current dogma (57) , p21 WAF1/CIP1 induces G 2 /M phase arrest by inhibiting cyclin B/Cdc2 (Cdk1). While p53 and p21 WAF1/CIP1 are not required for initiating G 2 /M cell cycle arrest, they seem to be critical for sustaining it. Cells lacking p53 and p21 WAF1/CIP1 exit prematurely from the G 2 /M cell cycle arrest and either enter mitosis or reinitiate DNA replication (10) , which causes genomic instability and can lead to accumulation of oncogenic mutations.
In p53-deficient cells G 2 /M arrest is initiated by the protein kinases ataxia telangiectasia-mutated kinase (ATM) and ataxia telangiectasia and Rad3-related kinase (ATR) (37) . Both enzymes are phosphatidylinositol 3-kinase (PI3-kinase)-related proteins that phosphorylate multiple substrates in response to DNA damage or replication blocks (26, 42) . Both ATM and ATR recognize DNA strand breaks and contain signaling and repair activity (5, 15, 39, 61) . The kinases Chk1 and Chk2 are downstream effectors of ATM and ATR, which induce G 2 /M cell cycle arrest by inactivating cdc25 tyrosine phosphatases through phosphorylation (4). cdc25 is required for removal of inhibitory phosphotyrosines on cyclin B/Cdc2 and cyclin A/Cdk2 kinase complexes that mediate entry into mitosis (9) . Interestingly, ATM/ATR are upstream activators of both the p53-and Chk1/2-cdc25 signaling pathways (46) . Cadmium (Cd) is a toxic transition metal with no known physiological role in higher eukaryotic organisms. It is widely used in the manufacturing industry, is present in cigarette smoke, and plays an important role as an environmental pollutant in contaminated food and water (2, 44) . One of the major targets of Cd 2ϩ -induced damage are the kidneys, where it accumulates preferentially in the proximal tubule (PT), which may ultimately result in renal failure (16) . At the cellular level, Cd 2ϩ -induced nephrotoxicity is reflected by the formation of reactive oxygen species (ROS) (48) and cell death induction (29, 49) . Cd 2ϩ is also classified as a class 1 carcinogen and suspected of inducing cancer in many organs, including the kidney (25, 35) . Cd 2ϩ carcinogenesis involves multiple mechanisms, including DNA strand breaks as well as inhibition of DNA repair (reviewed in Refs. 7, 55) . Cd 2ϩ induces p53-dependent G 1 /S and/or G 2 /M cell cycle arrest in various cell lines expressing p53 (8, 12, 27, 60) . However, tumorigenesis (as part of a multistep process) frequently involves shedding of p53 function, thus preventing p53-triggered apoptotic responses to genetic damage and providing survival advantages to incipient mutated cancer cells at a number of subsequent steps in tumor progression (23) . In fact, Cd 2ϩ has been shown to disrupt p53 conformation, resulting in inhibition of its function (33) . Therefore it is imperative to understand cell cycle alterations and their impact on death and survival decisions in p53-deficient Cd 2ϩ -exposed cells, particularly of organs in which Cd 2ϩ carcinogenesis occurs. Only one study in cells with mutated p53 has reported Cd 2ϩ -induced cell cycle alterations, namely, increased mitotic arrest (22) .
Our aim was to investigate Cd 2ϩ -induced cell cycle arrest and cell death in a p53-inactivated kidney PT cell line. Here we demonstrate that 50 -100 M Cd 2ϩ induces ROS formation and DNA damage, which results in cell cycle arrest in the G 2 /M phase and is mediated by cdc2 phosphorylation. The Chk1/2 inhibitor UCN-01 prevents cdc2 phosphorylation and overcomes G 2 /M arrest, which leads to increased cell death in Cd 2ϩ -exposed cells. Hence Cd 2ϩ -induced G 2 /M phase arrest may contribute to survival of p53-deficient PT cells evolving from premalignant to malignant state and thereby promote renal Cd 2ϩ carcinogenesis.
MATERIALS AND METHODS

Materials.
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), ethidium bromide (EtBr), thymidine, deoxycytidine, and ␣-tocopherol were from Sigma-Aldrich (St. Louis, MO). CdCl 2 was from Merck (Darmstadt, Germany). Nocodazole, hydroxyurea (HU), and 2=-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5=-bi-1H-benzimidazole, 3HCl (H-33342) were from Calbiochem (EMD, La Jolla, CA). Dihydrorhodamine 123 (DHR123) was from Axxora (Lörrach, Germany). SDZ PSC 833 (PSC 833) was a gift from Novartis (Basel, Switzerland). 7-Hydroxystaurosporine (UCN-01) was a gift from the Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health (Bethesda, MD). Other chemicals were obtained at the highest grade available. Inhibitors and drugs were dissolved in water, ethanol, or dimethyl sulfoxide, as appropriate [Յ0.1% (vol/vol)].
Antibodies. Mouse monoclonal antibodies against cdc2 (sc-8395) and MDM2 (sc-965) were from Santa Cruz Biotechnology (Santa Cruz, CA); tyrosine 15-phosphorylated cdc2 (cdc2-p) specific rabbit monoclonal (10A11; no. 4539) and p53-specific rabbit polyclonal (no. 9282) antibodies were from Cell Signaling (Danvers, MA). Alexa Fluor 488 chicken anti-rabbit IgG was from Molecular Probes (catalog no. A21441). Horseradish peroxidase-conjugated donkey antirabbit IgG and sheep anti-mouse IgG were from GE Healthcare (Piscataway, NJ).
Cell culture. Immortalized p53-inactivated WKPT-0293 Cl.2 rat kidney PT cells were cultured as described previously (49) . Cells (passages 100 -130) were split two or three times per week before reaching confluence. For experiments, cells were seeded into 24-well plates and grown for 2 days before treatment, unless otherwise indicated.
Single-cell gel electrophoresis (comet) assay. The technique followed the protocol of Singh et al. (43) with slight modifications. Cells (1.0 -1.5 ϫ 10 4 ) were treated with Cd 2ϩ in serum-containing medium (SCM), washed once in cold phosphate-buffered saline (PBS), and harvested with a cell scraper. After centrifugation at 4,500 g for 3 min at 4°C, pellets were resuspended in 10 l of PBS, embedded, and lysed. DNA was allowed to unwind (1 mM EDTA, 300 mM NaOH, pH Ͼ13, 20 min) and subjected to electrophoresis in the same solution (18 -20 V, 300 mA, 15 min). DNA of individual cells was stained with EtBr (5 g/ml) for 5 min, rinsed in water, and analyzed by fluorescence microscopy. Cells were visualized under excitation/emission wavelengths ( ex/em) of 518/605 nm for EtBr with a Visichrome High Speed Monochromator system (Visitron Systems, Puchheim, Germany), which was connected to a Zeiss Axiovert 200M microscope (Carl Zeiss, Jena, Germany) equipped with a ϫ20 objective. Images were captured, acquired, and processed with MetaMorph software (Universal Imaging, Downingtown, PA). For each experimental time point and condition, ϳ80 cells in 5 randomly chosen areas were counted according to the absence (no damage) or presence of a fluorescent tail next to the head (damage).
Determination of cellular ROS levels. DHR123 is a cell-permeant, uncharged, nonfluorescent dye that is oxidized to the highly fluorescent rhodamine 123 ϩ . Cells (1.5 ϫ 10 4 ) were treated with Cd 2ϩ in SCM. When used, ␣-tocopherol (100 M) was preincubated for 1 h before addition of Cd 2ϩ . At each time point, medium was replaced with Hanks' balanced salt solution (HBSS) ϩ 2.5 M DHR123 ϩ 1 M PSC 833 and incubated in the dark for 30 min at 37°C. Cells were then washed once with HBSS and lysed in RIPA buffer for 10 min at 37°C. Cell lysate was measured at ex/em of 485/535 nm with a Berthold Mithras LB940 fluorescence microplate reader (Berthold Technologies, Bad Wildbad, Germany). Protein content of cell lysate was determined by the method of Lowry et al. (30) .
Cell cycle synchronization. Cells were synchronized in the S phase with a double thymidine block (24) . Into six-well plates 2.5 ϫ 10 3 and 4.5 ϫ 10 3 PT cells were plated for control and synchronization experiments, respectively, and remained in exponential growth during synchronization. After 24 h, cells were exposed to 1 mM thymidine in serum-free medium (SFM) for 8 h and then released for 4 h in the presence of 24 M deoxycytidine in SCM followed by a second thymidine block for a further 8 h. Cells were cultured further in SCM containing 24 M deoxycytidine. The double thymidine block increased cells in the S phase of cell cycle from 24.9 Ϯ 1.7% to 59.3 Ϯ 12.9% (Table 1) . For Cd 2ϩ experiments, synchronized cells were incubated for 2.5 h after the second thymidine block before the addition of Cd 2ϩ to permit progression into G2/M phase. Nocodazole is an agent that interferes with the polymerization of microtubules and causes cell cycle arrest in the G 2/M phase (24) . PT cells (1.5 ϫ 
Values are means Ϯ SD of 3-9 experiments. Flow cytometric analysis of cell cycle distribution of p53-inactivated WKPT-0293 Cl.2 rat kidney proximal tubule (PT) cells was performed as described in MATERIALS AND METHODS. Values in bold highlight characteristic alterations of cell cycle phases induced by thymidine and nocodazole synchronization (S and G2/M phase arrest, respectively) or Cd 2ϩ (G2/M phase arrest). Statistical analysis of control vs. experimental groups was performed with unpaired Student's t-test or 1-way ANOVA for comparison of multiple groups. *P Ͻ 0.01.
2.0% to 51.6 Ϯ 3.7% (Table 1 ). The increase of cells in the S or G2/M phase was mainly achieved at the expense of cells in the G 1 phase. After removal of nocodazole, the synchronized cells were treated with or without Cd 2ϩ in SCM. Interestingly, after thymidine or nocodazole synchronization was stopped and cells were allowed to grow again, most cells quickly progressed through the cell cycle to the G1 phase within 6 h.
MTT cell toxicity assay. The MTT assay measures cellular viability and can be used to assess, but not distinguish among, cell death, growth, and proliferation. The MTT method was modified as previously described (29) . The values were normalized to the control, which was equivalent to 100% cell viability. To account for the cell cycle arrest during synchronization, different cell numbers were plated for nonsynchronized and thymidine-treated cells to obtain a similar cell density before treatment with Cd 2ϩ .
Detection of apoptosis and necrosis with H-33342 and EtBr.
Staining and experiments were conducted essentially as previously described (29) . Briefly, control and Cd 2ϩ -treated cells were stained with 2 g/ml H-33342, followed by 5 g/ml EtBr incubation. Cells were visualized under ex/em of 350/460 and 518/605 nm for H-33342 and EtBr, respectively, as described above for the comet assay. Cells from five random microscopic fields of view at ϫ200 magnification were counted per dish, and the average percentages of apoptotic and necrotic cells were calculated.
Flow cytometric analysis of cell cycle distribution. The DNA and RNA intercalating fluorescent dye propidium iodide (PI) was used to quantify cellular DNA content and cell cycle distribution (17) . After treatment, PT cells were harvested by trypsin digestion and fixed in 70% ethanol at Ϫ20°C. Before analysis, cells were incubated with RNase A (20 g/ml) and stained with PI (50 g/ml) for 5 min. Samples were immediately analyzed by flow cytometry with a FACS Calibur flow cytometer (BD Biosciences). A total of 10,000 events were recorded per sample at FL2-H (wavelength 575 Ϯ 26 nm), and the cell fractions in sub-G1, G1, S, and G2/M phases were quantified in histograms with WinMDI software (version 2.9, Joseph Trotter).
Immunofluorescence staining. PT cells (3 ϫ 10 4 ) were cultured on coverslips (12 mm) pretreated with heat-inactivated fetal calf serum. Cells were fixed, permeabilized, and blocked as described previously (50) . Cells were incubated with cdc2-p(Tyr15) primary antibody (1:30) overnight at 4°C and with Alexa Fluor 488-conjugated secondary antibody (1:500) for 1 h in the dark and counterstained with H-33342 (1 g/ml) for 5 min. Cells were visualized with filters for Alexa Fluor 488 and H-33342 with ex/em of 480/535 nm and 360/460 nm, respectively. Images were captured, acquired, processed, and analyzed according to previous protocols (50) . For quantitative analysis, the fluorescence intensities of all cells per image (21-45 cells per image) from two representative images per experimental condition were analyzed, and each experiment was repeated four to seven times. Average intensity values of whole images minus background intensity values (image areas in which no cells were present) were calculated for each image with MetaMorph software. The number of cells per image was determined, and cellular fluorescence intensity per image was calculated according to the equation (average intensity Ϫ background intensity)/cell number. This analysis was performed for each image, and mean values were calculated for each experimental condition. Control experiments with no primary antibody were performed to show specificity of staining.
Immunoblotting. Cells were harvested and resuspended in ice-cold RIPA buffer containing phosphatase and protease inhibitors. Cells were sonicated and centrifuged at 14,000 g for 1 min, and the protein concentration in the supernatant was determined. Proteins (30 -100 g) were separated by SDS-PAGE, as previously described (50) , and incubated with primary antibodies overnight at 4°C (dilution 1:200, 1:500, 1:1,000, and 1:1,000 for cdc2, mdm2, p53, and cdc2-p, respectively). Horseradish peroxidase-conjugated IgG (1:5,000) was used as secondary antibody. cdc2-p(Tyr15) was quantified by densitometry by subtracting background intensity and determining the ratio of cdc2-p to total cdc2 signals.
Statistical analyses. All experiments were repeated at least three times. Representative data or means Ϯ SD are shown, unless otherwise indicated. Statistical analysis by unpaired Student's t-test was performed with Sigma Plot 11.0. For more than two groups, one-way ANOVA was used, assuming equality of variance, with least significant difference (LSD), Tukey, and Bonferroni post hoc tests for pairwise comparison with SPSS 15.0. Results with P Ͻ 0.05 were considered statistically significant.
RESULTS
A cell line from the S1 segment of rat PT (WKPT-0293 Cl.2) was immortalized by retroviral transfection with SV40 large T-antigen, resulting in p53 inactivation (58) . This results in sequestration of p53 by the viral large T-antigen and thereby prevents p53-induced expression of its target gene mdm2 (59) . Mdm2 is known to induce p53 ubiquitylation and thereby labels p53 for proteasomal degradation (18) . Hence we expected large amounts of p53 and a lack of mdm2 expression. As shown in Fig. 1 , rat kidney cortex homogenate, which contains a high percentage of PT, expressed low amounts of p53 (several higher-molecular-mass bands likely represent ubiquitylated p53; data not shown), whereas SV40-transfected cells expressed large amounts of sequestered p53. mdm2, a target gene of p53, was detected in rat kidney cortex homogenate (Fig. 1) . In contrast, in WKPT-0293 Cl.2 cells, no mdm2 was found, which confirms the absence of functional p53 in the cell line. fluorescence intensities (Fig. 2A) . The percentage of cells with DNA damage was significantly different from controls after exposure to 100 M Cd 2ϩ within an hour of exposure and remained significantly elevated at 3 and 6 h. Qualitatively similar results were obtained with 50 M Cd 2ϩ (data not shown).
The generation of ROS induced by Cd 2ϩ was next investigated with DHR123. As shown in Fig. 2B , Cd 2ϩ (50 and 100 M) caused a concentration-dependent increase in ROS as early as 1 h after Cd 2ϩ exposure. ROS reached a peak of 177.2 Ϯ 37.4% above controls (P Ͻ 0.025; n ϭ 9) after 1 h with 100 M Cd 2ϩ , whereas with 50 M Cd 2ϩ peak ROS formation was observed at 3 h (160.5 Ϯ 22.5% above controls; P Ͻ 0.05; n ϭ 4). At Cd 2ϩ exposure times of Ͼ3 h, ROS levels decreased again but did not reach control levels by 6 h. Incubation with the antioxidant ␣-tocopherol (100 M) slightly decreased ROS levels in nontreated cells, but coincubation of ␣-tocopherol prevented ROS formation induced by Cd 2ϩ (Fig. 2B ). -induced cell cycle arrest, ␣-tocopherol was used. As shown in the representative histogram, ␣-tocopherol (100 M) alone had no effect on cell cycle distribution compared with control cells (Fig. 2C and Table 2 ). One hundred micromolar Cd 2ϩ increased cell cycle arrest in the G 2 /M phase (arrow in Fig. 2C ; Table 2 ). The percentage of cells in the G 2 /M phase was significantly elevated by 4.9 Ϯ 2.0% (from 18.0 Ϯ 2.3% in controls to 22.9 Ϯ 2.3% in Cd 2ϩ -exposed cells) ( Fig. 2D ; Table 2 ). Coincubation with 100 M ␣-tocopherol, which abolishes ROS formation, prevented the increase of G 2 /M phase arrest induced by Cd 2ϩ (Fig. 2 , C and D; Table 2 ), indicating that cell cycle arrest induced by Cd 2ϩ is caused by ROS formation and subsequent DNA damage. Fig. 3A, left) . Similar findings were seen with nocodazole-synchronized PT cells (arrow in Fig. 3A, right) . Quantitative analysis showed that in nonsynchronized controls 50 M Cd 2ϩ for 6 h significantly increased the proportion of PT cells in the G 2 /M phase by 4.6 Ϯ 1.8% compared with 9.9 Ϯ 3.5% in nocodazolesynchronized cells (Fig. 3B) . Hence, nocodazole synchronization increased the difference between control and Cd 2ϩ -treated G 2 /M-arrested cells by approximately twofold. In contrast, no significant effect of Cd 2ϩ on other cell cycle phases was found (data not shown). These data indicate that by synchronizing the cells we increased the number of cells reaching the G 2 /M phase and hence the proportion of cells arrested in the G 2 /M phase because of Cd 2ϩ damage. After demonstrating that Cd 2ϩ induces cell cycle arrest in the G 2 /M phase, we investigated its impact on Cd 2ϩ -induced cell death, assuming that G 2 /M phase arrest reflects DNA damage and hence toxicity. First, we compared Cd 2ϩ toxicity in nonsynchronized and thymidine-synchronized cells, using the MTT cell viability assay. In Cd 2ϩ -exposed (50 M for 6 h) thymidine-synchronized PT cells, cell viability was significantly decreased by 11.2 Ϯ 4.2% in unsynchronized cells and by 27.1 Ϯ 4.3% in synchronized cells (i.e., the percentage of dead cells was increased accordingly) (Fig. 3C ). This approximately twofold increase in toxicity after synchronization correlates with the approximately twofold increase of cells in the G 2 /M phase after 50 M Cd 2ϩ treatment for 6 h in synchronized cells (see above and Fig. 3B ). Similar effects were observed in nocodazole-synchronized cells, in which Cd 2ϩ -induced cell viability was significantly decreased from 14.5 Ϯ 2.9% in unsynchronized controls to 23.5 Ϯ 2.8% (Fig. 3C) . To confirm the latter results, we performed H-33342/EtBr nuclear staining of PT cells for detection of apoptosis and necrosis, respectively. Apoptosis by Cd 2ϩ (50 M for 6 h) was significantly elevated in nonsynchronized PT cells compared with untreated controls (5.8 Ϯ 1.5% vs. 1.2 Ϯ 0.2%) (Fig. 3D) , which confirms previous observations (29) . The values obtained with the MTT test were always higher than those measured by H-33342/EtBr nuclear staining of PT cells. This occurs because the MTT test also measures the number of metabolically active cells and therefore reflects cell cycle arrest in Cd 2ϩ -exposed cells, which also results in a decrease of cell number compared with nonarrested cells. Cells synchronized with 0.33 M nocodazole for 6 h displayed 1.7 Ϯ 0.3% apoptosis, which is similar to that of unsynchronized cells, confirming that 0.33 M nocodazole is not toxic. Cd 2ϩ exposure (50 M for 6 h) significantly increased apoptosis of nocodazole synchronized cells by approximately twofold (from 5.8 Ϯ 1.5% to 10.2 Ϯ 1.5%; Fig. 3D (56) . We hypothesized that prevention of cell cycle arrest in the G 2 /M phase would result in inadequate DNA repair and hence increased cell death. First, we tested the effect of UCN-01 (0.3 M) on the cell cycle of unsynchronized PT cells. As exemplified in a representative histogram, incubation of PT cells with UCN-01 for 6 h increased the percentage of cells in the G 1 phase (from 42.1 Ϯ 2.4% to 62.4 Ϯ 4.0%) at the expense of S and G 2 /M phases (asterisk in Fig. 4A and Fig. 4B ; Table 3 ) since UCN-01 also arrests cells in the G 1 phase in a p53-independent manner (14, 40) . Significant increase in the proportion of G 2 /M phase cells by 50 M Cd 2ϩ for 6 h was abolished by coincubation with UCN-01 (arrow in Fig. 4A and Fig. 4B ; Table 3 ), indicating that inhibition of Chk1/2 by UCN-01 overcomes G 2 /M phase arrest induced by Cd 2ϩ . Similar results were obtained with 100 M Cd 2ϩ (data not shown).
Synchronization of PT cells increases proportion of
We then investigated the effect of UCN-01 on cell viability of nonsynchronized PT cells. After 6-h exposure, cell viability was nonsignificantly reduced by 9.7 Ϯ 3.7% with UCN-01 and significantly by 15.8 Ϯ 6.7% with 50 M Cd 2ϩ (i.e., the percentage of dead cells was increased accordingly) (Fig. 4C) . Exposure of PT cells to 100 M Cd 2ϩ for 6 h decreased cell viability even more (by 39.0 Ϯ 5.5%). Coincubation of 0.3 M UCN-01 with 50 or 100 M Cd 2ϩ for 6 h reduced cell viability by 34.2 Ϯ 7.2% and 59.3 Ϯ 11.2%, respectively (Fig. 4C) , which is significantly higher than the effects obtained with Cd 2ϩ alone. The increase of cell death induced by UCN-01 was exclusively caused by apoptosis in PT exposed to 50 M Cd 2ϩ , whereas with 100 M Cd 2ϩ necrosis was also significantly increased (Fig. 4D) .
Cd 2ϩ increases phosphorylation of cdc2 at tyrosine 15 in PT cells, which is prevented by UCN-01.
To further detail the mechanism of Cd 2ϩ -induced cell cycle arrest at the G 2 checkpoint, we investigated the role of cdc2 (also known as cdk1 or p34 cdk1 ) as the end point of all cascades leading to G 2 arrest. Cdc25 phosphatase dephosphorylates cdc2 at Tyr15 to induce mitosis (see DISCUSSION for details) (19, 21, 45) . We used a Tyr15 phosphorylation-specific cdc2 antibody to determine levels of inactive phosphorylated cdc2 protein [cdc2- Values are means Ϯ SD of 4 experiments. PT cells were preincubated for 1 h with 100 M ␣-tocopherol followed by treatment with 100 M Cd 2ϩ for 6 h. Cells were then analyzed by flow cytometry after fixation and propidium iodide staining, as described in MATERIALS AND METHODS. Cell cycle distribution was determined with WinMDI software. Value in bold highlights G2/M phase arrest induced by Cd 2ϩ . Cotreatment with ␣-tocopherol prevents G2/M arrest. p(Tyr15)]. Immunofluorescence studies showed positive cdc2-p(Tyr15) staining in control cells, but not when the primary antibody was omitted, confirming specificity of cdc2-p staining and indicating that cdc2-p(Tyr15) is present under basal conditions (Fig. 5A) . To further validate the immunofluorescence signals, PT cells were also treated with the positive control 50 M HU for 24 h to induce cdc2-p(Tyr15) (Fig. 5) (38) . The cdc2-p staining was mainly nuclear, but some cytosolic staining was also observed. Exposure of PT cells to 50 M Cd 2ϩ for 4 h increased cdc2-p(Tyr15) staining (Fig. 5A) . Similar effects were also observed after 1 and 2 h (data not shown) as well as with 100 M Cd 2ϩ for 4 h (Fig. 5A ). Quantitative analysis demonstrated significant increases of cdc2-p(Tyr15) with 50 and 100 M Cd 2ϩ (Fig. 5B) . To confirm these observations immunoblots were also performed. Protein loading was controlled by using antibodies against cdc2, which also demonstrated that total cdc2 expression is not affected by the various experimental treatments. In PT cells treated with 50 M HU for 24 h cdc2-p(Tyr15) was significantly increased (Fig. 6, A and B) . Furthermore, significant increases of cdc2-p(Tyr15) with 100 M Cd 2ϩ exposure of PT cells were observed after 2 and 4 h (Fig. 6, A and B) . These data indicate that the G 2 damage checkpoint is activated by Cd 2ϩ , possibly through prevention of Tyr15 cdc2-p dephosphorylation by cdc25c, which results in cell cycle arrest in the G 2 phase.
Further evidence for this mechanism was also provided with the Chk1/2 inhibitor UCN-01 in immunofluorescence staining experiments with cdc2-p(Tyr15) antibody. A decrease in cdc2-p fluorescence intensity was clearly visible in cells treated with UCN-01 alone (Fig. 5A) and was significant after quan- titative analysis (68.3 Ϯ 16.1% of control staining; P Ͻ 0.01; n ϭ 6). Likewise, cdc2-p was attenuated when PT cells were coincubated with 0.3 M UCN-01 and 100 M Cd 2ϩ for 4 h (Fig. 5A) . A highly significant decrease in cdc2-p(Tyr15) between PT cells treated with Cd 2ϩ and UCN-01 ϩ Cd 2ϩ -treated cells was observed (Fig. 5B) .
Immunoblotting showed that treatment with 0.3 M UCN-01 alone for 4 h also significantly decreased levels of cdc2-p(Tyr15) compared with untreated controls (Fig. 6, C and D) , which confirms the immunofluorescence data (Fig. 5) . When PT cells were coincubated with 100 M Cd 2ϩ and 0.3 M UCN-01, the increase of cdc2-p(Tyr15) levels induced by 100 M Cd 2ϩ was reduced to the levels obtained with UCN-01 alone, which is in line with the immunofluorescence data (Fig. 6, C and D) . This indicates an involvement of the Chk1/2 pathway in Cd 2ϩ -mediated prevention of Tyr15 cdc2-p dephosphorylation by cdc25c resulting in G 2 phase cell cycle arrest.
DISCUSSION
The induction of oxidative stress and formation of reactive oxygen and nitrogen species in vivo and in vitro is an attractive hypothesis to account for mutagenic and carcinogenic effects of , respectively. Cotreatment with UCN-01 overcomes G2/M arrest. metals in mammalian cells because these radicals are known to cause oxidative damage to lipids, proteins, and DNA (7). Indeed, Cd 2ϩ induces rapid and concentration-dependent ROS formation in kidney PT cells (Fig. 2B) , which is paralleled by development of DNA damage ( Fig. 2A) . Although Cd 2ϩ is not capable of exerting redox reactions in biological systems, it induces ROS formation in cultured cells of various origins and in vivo, including kidney PT cells, by depletion of endogenous redox scavengers, inhibition of antioxidative enzymes, inhibition of the mitochondrial electron transport chain, and/or displacement of redoxactive metals (reviewed in Ref. 47) . In the present study we show that ROS mediate Cd 2ϩ -induced G 2 checkpoint arrest in p53-deficient kidney PT cells (Fig. 2, C and D) , although direct DNA-damaging effects of Cd 2ϩ and/or inhibition of DNA mismatch repair may also occur (7, 55) . Furthermore, Cd 2ϩ -induced p53-independent G 2 checkpoint arrest can be increased in S or G 2 /M phase synchronized cells (Fig. 3) .
In normal cells DNA damage induced by oxidative stress leads to cell cycle arrest at the G 1 and G 2 /M cell cycle checkpoints (6) . Although p53 mediates cell cycle arrest in the G 1 phase and G 2 /M phases, the G 2 /M checkpoint is especially important for understanding cell cycle alterations and death and survival decisions linked to growth and differentiation in p53-deficient cells, such as premalignant or malignant cells. Cells deficient in p53 rely on ATM/ATR-mediated checkpoint signaling for survival (28, 37) . The activity of cdc2 is strictly regulated as it is the end point of all cascades leading to G 2 arrest. The critical regulatory step in the activation of cdc2 during progression from the G 2 phase into mitosis is dephosphorylation of cdc2 at Tyr15, which is carried out by cdc25c (19, 21, 45) . Hence activation of ATM/ATR by DNA damage initiates a signaling cascade, which inactivates cdc25c and thereby prevents dephosphorylation of cdc2 at Tyr15 to induce mitosis. Here we further demonstrate that Cd 2ϩ -induced G 2 /M cell cycle arrest correlates with an increase of cdc2 phosphorylation at Tyr15 (Figs. 5 and 6 ), indicating that ROS-induced DNA damage activates the ATM/ATR signaling pathway, and thus Chk1/2, to induce G 2 checkpoint arrest. A previous study in the p53-proficient rat PT cell line NRK-52E demonstrated G 2 /M phase arrest mediated by Cd 2ϩ (60) . The authors observed upregulation of p53 and p21 WAF1/CIP1 that was held responsible for mediating inhibition of Cdk1 and Cdk2 and, as expected, resulted in G 2 /M arrest. Surprisingly, p53 upregulation induced by Cd 2ϩ was not associated with G 1 phase arrest. Multiple overlapping upstream signals may have triggered p53 activation (57), including ATM/ATR, but this was not investigated further.
UCN-01 overcomes cell cycle arrest in the G 2 phase by targeting Chk1/2 (11, 20, 62) . In the presence of UCN-01 Cd 2ϩ -induced cdc2-p(Tyr15) phosphorylation was abolished and even decreased compared with controls (Fig. 5, Fig. 6 , C and D), which is in line with the presumed mode of action of UCN-01 and suggests that under these conditions cdc2 was more active to promote mitosis. Accordingly, cell cycle arrest induced by Cd 2ϩ was also abolished (Fig. 4, A and B) . Interestingly, by overcoming G 2 checkpoint arrest with UCN-01, Cd 2ϩ -induced cell death was increased (Fig. 4, C and D) . This indicates that the G 2 /M cell cycle arrest induced by Cd 2ϩ occurs in a population of damaged PT cells that can potentially die unless this DNA damage is partially or completely fixed. Active cdc2 is also a key player in the regulatory processes linking cell cycle arrest to apoptosis via the dissociation of the survivin/caspase 9 complex and by inhibiting B cell lymphoma 2 (Bcl-2), an antiapoptotic protein (13) . Prevention of G 2 checkpoint arrest by UCN-01 gives Cd 2ϩ -damaged cells no opportunity to repair damaged DNA and in turn precipitates entry of these p53-inactivated PT cells into mitosis (10) concluding with apoptosis ( Fig. 4D ) (possibly via caspase 9 activation and Bcl-2 inhibition). Alternatively, cells can undergo mitotic catastrophe (37, 52) .
It is well established that p53 inactivation provides an advantage to premalignant cells (23) . At first sight, G 2 /M phase arrest of p53-inactivated cells provides an opportunity for repair of DNA damage. However, this mechanism turns out to be a double-edged sword because repair mechanisms have a limited fidelity, which allow some nonlethal mutations to slip through when p53-inactivated cells exit prematurely from the G 2 /M cell cycle arrest and enter mitosis (10) . The worst-case scenario occurs when mutations are generated, which promote cell survival and/or proliferation. They are passed on to subsequent generations of cells, which may eventually evolve into malignant cells. UCN-01 represents a therapeutic strategy that takes these considerations into account, and in fact it has been shown to increase the cytotoxicity of chemotherapy and radiation (31, 41, 51) . Consequently, UCN-01 is currently used in clinical trials.
In summary, Cd 2ϩ induces cellular stress in p53-inactivated kidney PT cells, leading to ROS formation and DNA damage. This triggers activation of the ATM/ATR pathway, which abrogates dephosphorylation of cdc2/cyclin B complex at cdc2-p(Tyr15). This results in G 2 checkpoint cell cycle arrest to provide an opportunity for DNA repair and delays entry of p53-inactivated PT cells into mitosis. The inhibitor of the ATM/ATR pathway UCN-01, which targets Chk1/2 upstream kinases and thereby enhances cdc25c-mediated dephosphorylation of cdc2, overcomes G 2 checkpoint arrest. Hence Cd 2ϩ -damaged cells enter mitosis and die. The data suggest that in DNA-damaged p53-inactivated kidney PT cells induced by Cd 2ϩ , G 2 checkpoint arrest may allow premalignant cells to survive and subsequently develop into malignant cells. D) . At the indicated times cells were harvested and lysed in RIPA buffer containing phosphatase inhibitors. Proteins (50 g) were separated by SDS-PAGE and probed for cdc2-p(Tyr15) (1:1,000) or cdc2 (1:200). Cdc2 antibody was used to determine total cdc2 expression. Blots (A, C) were scanned, and signals were quantified by densitometric analysis (B, D). Cdc2-p(Tyr15) was quantified as described in MATERIALS AND METHODS. Means Ϯ SD of 3-6 experiments are shown. Statistical differences between controls and experimental groups as well as among experimental groups were calculated with 1-way ANOVA for comparison of multiple groups.
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